journal article·2024-01

Overcoming ROS Resistance of Photodynamic Therapy with Self‐Assembled Nano‐Prodrugs for Efficient Triple‐Negative Breast Cancer

Bowen Li, Jianwu Tian, Xin Xie, Fu Zhang, Chongzhi Wu, Yi Shan, Guobin Qi, Wentao Song, Yuan Ping, Bin Liu

Advanced Functional Materials· Volume 34· Issue 4
Publisher page

Abstract

Abstract Triple‐negative breast cancer (TNBC) is endowed with a highly aggressive nature that results in distant metastases and high recurrence rates, yet limited success is realized in traditional chemotherapy. Activatable photosensitizers (PSs) may provide an effective and non‐invasive strategy to induce TNBC cell death in a precise way by offering stimuli‐responsive reactive oxygen species (ROS). However, the toxicity of ROS is often mitigated and even devitalized by the instinctive behavior of ROS resistance in TNBC cells. To address this issue, herein a small molecular self‐assembly nano‐prodrug is presented to co‐deliver an activatable PS and ROS resistance inhibitor. In TNBC cells, the overexpressed glutathione can disassemble the nano‐prodrug, thereby releasing ROS resistance inhibitor and activating the PS for photodynamic therapy and fluorescence imaging. A hybrid membrane coating‐assisted nanoparticle formation strategy is further demonstrated for efficient inhibition of tumor growth and distant metastases on both subcutaneous and orthotopic TNBC mice models.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Click Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical and Biomolecular Engineering National University of Singapore 4 Engineering Drive 4 Singapore 117585 Singapore

College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P. R. China

Funding

National University of Singapore · National Research Foundation Singapore · National Natural Science Foundation of China

References (66)

Show source-provided references
1. 10.1038/s41523-022-00468-010.1038/s41523-022-00468-0 ↗
2. 10.3322/caac.2170810.3322/caac.21708 ↗
3. 10.1056/NEJMra100138910.1056/NEJMra1001389 ↗
4. 10.5306/wjco.v6.i6.25210.5306/wjco.v6.i6.252 ↗
5. 10.1093/oncolo/oyab00310.1093/oncolo/oyab003 ↗
6. 10.1038/nrclinonc.2016.6610.1038/nrclinonc.2016.66 ↗
7. Zhu Y. X. · Acta Rev. Cancer. · 2021 · 1876
8. 10.1007/s12282-011-0254-910.1007/s12282-011-0254-9 ↗
9. 10.1021/acsnano.3c0032610.1021/acsnano.3c00326 ↗
10. 10.1021/acs.chemrev.1c0038110.1021/acs.chemrev.1c00381 ↗
11. 10.1039/D1SC00045D10.1039/D1SC00045D ↗
12. 10.1021/acsnano.9b0166510.1021/acsnano.9b01665 ↗
13. 10.1021/cr900236h10.1021/cr900236h ↗
14. 10.1002/adfm.20160405310.1002/adfm.201604053 ↗
15. 10.1021/acsabm.0c0127410.1021/acsabm.0c01274 ↗
16. 10.1002/adhm.20210201710.1002/adhm.202102017 ↗
17. 10.1002/anie.20191352210.1002/anie.201913522 ↗
18. 10.1039/C7SC03454G10.1039/C7SC03454G ↗
19. 10.1039/D2CS00673A10.1039/D2CS00673A ↗
20. 10.1021/acs.jmedchem.6b0124310.1021/acs.jmedchem.6b01243 ↗
21. 10.1016/j.pmatsci.2020.10068510.1016/j.pmatsci.2020.100685 ↗
22. 10.1016/j.drup.2004.01.00410.1016/j.drup.2004.01.004 ↗
23. 10.1186/s12951-021-00952-y10.1186/s12951-021-00952-y ↗
24. 10.1016/j.advms.2017.05.00510.1016/j.advms.2017.05.005 ↗
25. 10.1016/j.ajme.2017.09.00110.1016/j.ajme.2017.09.001 ↗
26. 10.2174/09298671179584327210.2174/092986711795843272 ↗
27. 10.1039/D0SC04983B10.1039/D0SC04983B ↗
28. 10.1038/cddis.2016.10510.1038/cddis.2016.105 ↗
29. 10.1038/s41568-021-00435-010.1038/s41568-021-00435-0 ↗
30. 10.1016/j.cej.2022.13858510.1016/j.cej.2022.138585 ↗
31. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
32. 10.1111/j.1476-5381.2011.01480.x10.1111/j.1476-5381.2011.01480.x ↗
33. 10.1016/j.gendis.2020.11.01010.1016/j.gendis.2020.11.010 ↗
34. 10.1002/cbf.358110.1002/cbf.3581 ↗
35. Seibt T. M. · Biol. Med. · 2019 · 133 · 144
36. 10.1371/journal.pone.019515110.1371/journal.pone.0195151 ↗
37. 10.7150/thno.3286710.7150/thno.32867 ↗
38. 10.1021/acsnano.2c0809810.1021/acsnano.2c08098 ↗
39. 10.3389/fonc.2022.85846210.3389/fonc.2022.858462 ↗
40. 10.1007/s13238-020-00789-510.1007/s13238-020-00789-5 ↗
41. Lin W. Y. · Am. J. Cancer Res. · 2020 · 10 · 3106
42. 10.1002/adhm.20230145310.1002/adhm.202301453 ↗
43. 10.1016/j.bbcan.2023.18889010.1016/j.bbcan.2023.188890 ↗
44. 10.1016/j.ejphar.2022.17479710.1016/j.ejphar.2022.174797 ↗
45. Fu Q. · Chin. Chem. Let.
46. 10.1172/JCI12404910.1172/JCI124049 ↗
47. 10.1038/s41419-021-03998-w10.1038/s41419-021-03998-w ↗
48. 10.1002/adfm.20180069210.1002/adfm.201800692 ↗
49. 10.1021/acs.nanolett.8b0073710.1021/acs.nanolett.8b00737 ↗
50. 10.1016/j.nantod.2022.10148010.1016/j.nantod.2022.101480 ↗
51. 10.1016/j.jconrel.2015.10.00610.1016/j.jconrel.2015.10.006 ↗
52. 10.1016/j.bbcan.2022.18870310.1016/j.bbcan.2022.188703 ↗
53. 10.1002/adma.20080139310.1002/adma.200801393 ↗
54. 10.1021/acsnano.5b0318410.1021/acsnano.5b03184 ↗
55. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
56. 10.1016/j.addr.2023.11470810.1016/j.addr.2023.114708 ↗
57. 10.2217/nnm.16.510.2217/nnm.16.5 ↗
58. 10.1016/j.nantod.2011.10.00110.1016/j.nantod.2011.10.001 ↗
59. Xuan L. H. · Med. Comm. · 2023 · 4
60. 10.1021/jacs.5b0409710.1021/jacs.5b04097 ↗
61. 10.1126/sciadv.abc172510.1126/sciadv.abc1725 ↗
62. 10.1038/s41467-019-11193-x10.1038/s41467-019-11193-x ↗
63. 10.1016/j.apsb.2022.02.00710.1016/j.apsb.2022.02.007 ↗
64. 10.1021/acsnano.1c0380010.1021/acsnano.1c03800 ↗
65. 10.1186/s12951-020-00649-810.1186/s12951-020-00649-8 ↗
66. 10.1016/j.mtbio.2023.10072210.1016/j.mtbio.2023.100722 ↗